We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Arya Sciences Acquisition Corp. III (“ARYA” or the “Company”) (NASDAQ: ARYA) in connection with the Company’s proposed merger with Nautilus Biotechnology, Inc. (“Nautilus”), a privately-held startup mapping human proteins.  Under the terms of the merger agreement, ARYA will acquire Nautilus through a reverse merger that will result in Nautilus becoming a becoming a public company traded on the NASDAQ.  The transaction implies an enterprise value for the combined company of approximately $350 million.

WeissLaw LLP is investigating whether ARYA’s board acted in the best interest of ARYA’s public shareholders in agreeing to the proposed transaction, whether the board was fully informed as to the valuation of Nautilus, and whether all information regarding the process undertaken by the board and the valuation of the transaction will be fully and fairly disclosed to ARYA public shareholders. WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com